Acepodia, Inc.

Acepodia Announces First Patient Dosed in Phase 1 Trial of ACE723, a Novel Dual-Payload Antibody-Drug Conjugate

ACE723 is the first candidate from Acepodia's AD2C platform to enter human testing ALAMEDA, Calif., and TAIPEI, Nov. 5, 2026 — Acepodia (6976: TT), a…